Treatment of Atopic Dermatitis by a Full-Body Blue Light Device

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

87 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-16

Study Completion Date

2018-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multicentric, placebo-controlled, double-blinded, three-armed, prospective, randomized controlled trial.150 patients diagnosed with atopic dermatitis will be randomized to arm 1 (irradiation for 30min at 415nm wavelength), arm 2 (irradiation for 30min at 450nm wavelength), and arm 3 (irradiation for 30min at low-dose (placebo)). Irradiation will be scheduled 3 times a week for 8 weeks. Patients will be followed up for four weeks after the last irradiation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Narrowband UVB Phototherapy on Systemic Inflammation in Patients With Atopic Dermatitis

NCT03083730

Atopic Dermatitis

COMPLETED NA

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects

NCT03058783

Atopic Dermatitis

COMPLETED PHASE3

Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults

NCT01232985

Atopic Dermatitis Pruritus

COMPLETED PHASE2

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)

NCT03002571

Atopic Dermatitis

COMPLETED PHASE3

Medium-Dose UVA1 Versus Narrow-Band UVB in Atopic Dermatitis

NCT00419406

Atopic Dermatitis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dermatitis, Atopic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Patients are blinded by wearing tinted glasses for eye protection which disenable distinction of different wave lengths of light. Medical doctors will examine patients in other rooms than those equipped with the investigational medical devices. These examiners are blinded and are therefore not involved in the preparation and process of the irradiation.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Blue light at 415nm

Full body irradiation for 30min (15 min. each body side) with blue light at 415nm peak wavelength with full body blue device.

Group Type EXPERIMENTAL

Full Body Blue Light Device

Intervention Type DEVICE

Full body blue light irradiation (phototherapy) of atopic dermatitis patients.

Blue light at 450nm

Full body irradiation for 30min (15 min. each body side) with blue light at 450nm peak wavelength with full body blue device.

Group Type EXPERIMENTAL

Full Body Blue Light Device

Intervention Type DEVICE

Full body blue light irradiation (phototherapy) of atopic dermatitis patients.

Placebo

Full body irradiation for 30min (15 min. each body side) with blue light at 450nm peak wavelength with a low dose setting (not therapeutically active) of the full body blue device.

Group Type PLACEBO_COMPARATOR

Full Body Blue Light Device

Intervention Type DEVICE

Full body blue light irradiation (phototherapy) of atopic dermatitis patients.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Full Body Blue Light Device

Full body blue light irradiation (phototherapy) of atopic dermatitis patients.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed and dated informed consent prior to any study mandated procedure
* Good health as determined by the Investigator
* Willing and able to comply with study requirements
* Atopic dermatitis (AD) fulfilling the United Kingdom (UK) criteria of AD
* Age between 18 and ≤ 75 years
* Reliable method of contraception for women of childbearing potential (i.e. low failure rate less than 1% per year; e.g. oral contraceptives, intrauterine device \[IUD\] or transdermal contraceptive patch)
* Willing to abstain from excessive sun / UV exposure (e.g. sunbathe, solarium) during the course of the study
* Body Mass Index ≥ 18 and ≤ 35

Exclusion Criteria

General

* Inmates of psychiatric wards, prisons, or other state institutions
* Investigator or any other team member involved directly or indirectly in the conduct of the clinical study
* Participation in another clinical trial within the last 30 days
* Pregnant or nursing women
* Risk of non-compliance with study procedures

Medical History

* Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases may include cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, endocrine disease or pulmonary disease, and others.
* Clinically relevant abnormalities in hematology, or blood chemistry at screening.
* Positive HIV-1/2Ab, hepatitis B surface antigen (HBsAg) or hepatitis C virus antibodies (HCV-Ab) test at screening.
* Diastolic blood pressure above 95 mmHg.
* Febrile illness within 2 weeks prior to baseline visit.
* Alcohol or drug abuse within 12 months prior to screening (i.e., Regular daily consumption of more than 1 liter of beer or the equivalent quantity of approximately 40 g of alcohol in another form.)
* Photodermatosis and/or significant photosensitivity, including porphyria and/or hypersensitivity to porphyrins as well as photosensitivity due to present or past (within the last year) intake of amiodarone.
* Congenital or acquired immunodeficiency
* Patients who have been diagnosed with invasive skin cancer at any time (=malignant cells invaded below the basal membrane of the epidermis), or with severe actinic damage present at baseline visit.
* Patients with genetic deficiencies attached with increased sensitivity to light or increased risk to dermatologic cancer (i.e. Xeroderma pigmentosum, Cockayne Syndrome, Bloom-Syndrome).

Concomitant medication/treatment in medical history and during the study

Within 8 weeks prior to baseline visit:

* Systemic immunosuppression treatment (steroids, cyclosporine, azathioprine, Mycophenolate Mofetil (MMF))

Within 4 weeks prior to baseline visit:

* UV radiation treatment

Within 2 weeks prior to baseline visit:

* Topical steroid treatment
* Topical calcineurin inhibitor treatment

Within 3 days prior to baseline visit:

* Photo-sensitising medication (e.g. psoralen, tetracyclines, hydrochlorothiazide, phenothiazines, quinolones, hypericumperforatum, arnica, valerian, tar) as assessed by the regular medication plan of the patient
* colours (e.g. thiazide, toluidine blue, eosin, methylene blue, rose Bengal, acridine) which will be visible on the patient's skin

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No